^
    over1year
    Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study. (PubMed, Oncologist)
    Anlotinib showed moderate antitumor activity in drug-resistant GIST cell lines in vitro, and good PFS and better tolerance in second-line therapy study.
    Preclinical • Clinical Trial,Phase II • Journal • Stroma • Metastases
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    KIT mutation • KIT N822K • KIT exon 13 mutation • KIT V654A • KIT D820A
    |
    imatinib • Focus V (anlotinib) • sunitinib